Enterococcus cecorum empyema thoracis successfully treated with cefotaxime

J Clin Microbiol. 2004 Feb;42(2):919-22. doi: 10.1128/JCM.42.2.919-922.2004.

Abstract

We report the first case of Enterococcus cecorum empyema thoracis and spontaneous bacterial peritonitis in a 44-year-old man with underlying cirrhosis. The patient responded to cefotaxime (MIC, 0.25 microg/ml) treatment and drainage of the empyema. Susceptibility of E. cecorum to expanded-spectrum cephalosporins could be due to its production of types of penicillin-binding proteins similar to those produced by Streptococcus species rather than to those produced by Enterococcus species (as predicted by phylogenetic analysis of the 16S rRNA gene sequences).

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use*
  • Asian People
  • Cefotaxime / therapeutic use*
  • China
  • Empyema / drug therapy
  • Empyema / microbiology
  • Enterococcus* / classification
  • Enterococcus* / drug effects
  • Enterococcus* / isolation & purification
  • Gram-Positive Bacterial Infections / diagnosis*
  • Gram-Positive Bacterial Infections / drug therapy
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Molecular Sequence Data
  • Phylogeny

Substances

  • Anti-Bacterial Agents
  • Cefotaxime

Associated data

  • GENBANK/AY365054